查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856209

中枢神经系统生物标记市场按类型、适应症、技术、应用和最终用户划分－2025-2032年全球预测

Central Nervous System Biomarkers Market by Type, Disease Indication, Technology, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，中枢神经系统生物标记市场规模将达到 88.3 亿美元，复合年增长率为 7.92%。

主要市场统计数据
基准年 2024 48亿美元
预计年份：2025年 51.9亿美元
预测年份：2032年 88.3亿美元
复合年增长率 (%) 7.92%

权威概述揭示了中枢神经系统生物标记为何正成为神经病学诊断、治疗和转化决策的重要工具。

引言部分阐述了中枢神经系统生物标记是提高诊断清晰度、加速治疗研发以及在神经病学和精神病学领域实现精准治疗的关键工具。在过去十年间，分子生物学、分析化学和计算分析的融合已将生物标记从探索性工具转变为临床研究和转化流程中不可或缺的组成部分。因此，学术界、临床实践和产业界的相关人员开始将生物标记视为可操作的信号，而不仅仅是疾病的相关因素，这些信号有助于优化临床检测、指导治疗并对患者进行分层。

技术整合、转化合作和标准化努力再形成中枢神经系统生物标记的发展，这是关键性的变革。

中枢神经系统生物标记领域的变革性转变反映了技术的成熟、临床重点的演变以及连接学术界和产业界的新兴合作研究模式。质谱和新一代定序技术的创新提高了检测灵敏度，降低了低丰度分析物的检测极限，从而扩大了可测量标靶的范围，并增强了周边血液和脑脊髓液生物标记的临床效用。同时，免疫检测的改进，包括高亲和性试剂和自动化平台的应用，提高了不同临床实验室的检测结果重复性。

对 2025 年更新的美国关税措施如何影响试剂供应链、检测采购决策以及生物标记工作流程的营运弹性进行全面分析。

包括关税表和海关程序变更在内的政策和贸易措施，已于2025年实施，对中枢神经系统生物标记研发的供应链、试剂采购和成本结构产生了累积影响。进口关税和处理延误往往导致专用试剂、抗体试剂盒、质谱耗材和定序试剂的前置作业时间延长，而这些试剂通常需要从全球采购。因此，采购团队和实验室管理人员重新审视了库存策略，转向更多元化的供应商组合，并加快了对替代试剂来源的资格确认，以确保研究进度。

深度细分智慧整合生物标记类型、适应症、技术、应用和最终用户角色，以支援策略优先排序和转换规划。

深入的細項分析表明，生物标记类型、适应症、技术模式、应用以及最终用户群体特征均会影响其临床应用路径。在众多生物标记类型中，基因生物标誌物提供有关基因和体细胞突变的信息，并能揭示疾病机制和患者分层。同时，代谢组生物标记能够灵敏地检测生化通道的扰动，而蛋白质组生物标记则可以直接测量蛋白质丰度、转译后修饰和聚集体，这些通常与神经病理学密切相关。这些互补的方法正越来越多地被联合使用，以建构多层次的分子特征。

区域情报揭示了美洲、欧洲、中东和非洲以及亚太地区的能力、法规环境和基础设施如何影响生物标记的应用和检测设计。

我们揭示了不同地区在能力、基础设施成熟度和法规环境的差异如何影响中枢神经系统生物标记的发现、检验和应用。在美洲，学术研究和生物技术创新领域的卓越中心正在推动新型检测方法快速转化为临床试验，而成熟的合约研究和中心实验室服务体系则为复杂的多中心专案提供支援。同时，报销动态和支付方参与在临床应用中发挥核心作用，推动早期经济证据的产生以及分析检验。

诊断开发商和服务供应商之间的竞争与合作动态揭示了平台差异化、建立伙伴关係和应对监管的策略。

活跃于中枢神经系统生物标记领域的公司之间的竞争与合作，体现了它们在平台专业化、临床试验伙伴关係以及附加价值服务的差异化策略。一些公司专注于开发经过深度检验的检测平台，强调分析性能和符合临床应用监管要求的应对力。这些公司投入大量资金进行外部验证研究，以确保试剂品质、批间一致性和临床可靠性。相反，其他公司则致力于提供整合式解决方案，将检测化学、数据分析、临床实验室支援和监管咨询相结合，从而降低寻求生物标记终点的申办者的门槛。

为产业领导者提供切实可行的策略建议，以加速生物标记验证、强化供应链并协调监管和商业性管道，促进其临床应用。

产业和临床研究领导者应采取果断行动，实施一系列协调一致的优先事项，将生物标记的潜力转化为持续的临床和商业性价值。首先，在研发早期阶段就应投资于检测方法的稳健性和跨中心标准化，以减少后续验证的阻力。其次，整合多模态生物标记策略，结合多模态检测的丰富性，同时确保数据整合流程保持可追溯性和可解释性。

我们采用透明的混合方法研究途径，结合专家访谈、技术文献综述和资料三角验证，为生物标记开发的研究结果和实务建议提供了基础。

本分析的调查方法结合了定性和定量方法，以确保依证的可靠性，并对来自多个资料流的研究结果进行三角验证。主要研究包括对神经病学和精神病学领域的关键意见领袖、检测方法开发研究人员、临床运营总监和实验室主任进行深度访谈，以获得关于检测方法性能、运营瓶颈和推广应用促进要素的实证见解。这些访谈为解读技术进步和转化障碍提供了基础。

总结结论强调，强有力的验证、稳定的供应和跨部门伙伴关係对于实现中枢神经系统生物标记的临床潜力至关重要。

总之，中枢神经系统生物标记在实验室技术进步、临床需求和转化策略的交汇点上发挥关键作用。基因组学、蛋白质组学和代谢组学方法的共同应用，以及免疫检测、质谱和定序技术的进步，提高了临床效用的验证标准，同时也为精准诊断和标靶治疗创造了新的机会。转化应用的推进依赖于严格的检测验证、标准化的工作流程以及将研究队列与临床应用管道连接起来的强有力的伙伴关係。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合数位双胞胎模型和多体学中枢神经系统生物标记发现，实现个人化治疗方法选择。
  • 采用血脑障壁渗透性检测方法检验候选週边中枢神经系统生物标记在临床试验的应用
  • 脑脊髓液中外泌体微型RNA特征作为阿兹海默症早期检测的预后指标
  • 以突触密度为标靶的PET放射性配体作为神经退化研究中的定量生物标记的商业化开发
  • 运用人工智慧演算法分析中枢神经系统疾病进展研究中的纵向生物标记数据
  • 製药公司和诊断公司合作，共同开发用于治疗中枢神经系统肿瘤的伴随诊断方法

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 中枢神经系统生物标记市场（按类型划分）

  • 基因生物标誌物
  • 代谢组学生物标誌物
  • 蛋白质体学生物标誌物

9. 依适应症分類的中枢神经系统生物标记市场

  • 神经退化性疾病
  • 神经发育障碍
  • 精神疾病

10. 按技术分類的中枢神经系统生物标记市场

  • 免疫检测
    • ELISA法
    • 蛋白质印迹法
  • 质谱分析
    • 气相层析法联用
    • 液相层析法键合
  • 下一代定序
    • 目标序列
    • 全基因组定序

第十一章：中枢神经系统生物标记市场（按应用领域划分）

  • 诊断和治疗
  • 药物发现与开发
  • 个人化医疗
  • 预后
  • 研究与开发

第十二章：依最终使用者分類的中枢神经系统生物标记市场

  • 学术研究机构
  • 医疗保健提供者
  • 製药公司

13. 中枢神经系统生物标记市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 中枢神经系统生物标记市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国中枢神经系统生物标记市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Abbvie Inc.
    • Acumen Pharmaceuticals Inc.
    • ADx NeuroSciences NV
    • Agilent Technologies, Inc.
    • Altoida
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Bruker Corporation
    • C2N Diagnostics, LLC
    • Cerevance, LLC
    • Charles River Laboratories International, Inc.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche AG
    • Invicro LLC
    • Johnson & Johnson Services Inc.
    • Laboratory Corporation of America Holdings
    • Mediford Corporation
    • Merck & Co., Inc.
    • Myriad Genetics, Inc.
    • Neurotrack Technologies, Inc.
    • Novartis AG
    • Qiagen NV
    • Quanterix Corporation
    • Sanofi SA
    • Shimadzu Corporation
    • Siemens Healthineers
    • SynapCell
    • Thermo Fisher Scientific Inc.
Product Code: MRR-450A0628CEB3

The Central Nervous System Biomarkers Market is projected to grow by USD 8.83 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.80 billion
Estimated Year [2025] USD 5.19 billion
Forecast Year [2032] USD 8.83 billion
CAGR (%) 7.92%

An authoritative overview introducing why central nervous system biomarkers are becoming essential instruments for diagnostics, therapeutics, and translational decision-making across neurology

The introduction frames the evolving importance of central nervous system biomarkers as pivotal instruments for improving diagnostic clarity, accelerating therapeutic development, and enabling precision approaches in neurology and psychiatry. Over the past decade the convergence of molecular biology, analytical chemistry, and computational analytics has shifted biomarkers from exploratory tools to integral components of clinical research and translational pipelines. As a result, stakeholders across academia, clinical practice, and industry now view biomarkers not simply as correlates of disease but as actionable signals that inform trial enrichment, therapeutic targeting, and patient stratification.

In this context, genomic biomarkers, metabolomic signatures, and proteomic profiles each contribute complementary insights into disease biology, and advances in immunoassays, mass spectrometry, and next-generation sequencing have increased sensitivity and specificity for cerebrospinal fluid and peripheral samples. Consequently, clinicians and researchers are better equipped to detect early pathological changes, monitor treatment responses, and refine prognostic assessments. Moreover, regulatory authorities have signaled greater receptivity to biomarker-based evidence when it demonstrates clinical relevance and analytical robustness, which in turn motivates investment in assay validation and cross-site standardization.

Transitioning from discovery to deployment requires a multidisciplinary approach that aligns laboratory workflows, data governance, and clinical endpoints. Therefore, the remainder of this executive summary synthesizes transformative landscape shifts, policy influences, segmentation intelligence, regional dynamics, competitive behaviors, recommended actions for leaders, and the research methodology underpinning the findings.

Critical transformative shifts reshaping central nervous system biomarker development driven by technology integration, translational collaborations, and standardization efforts

Transformative shifts within the central nervous system biomarker landscape reflect technological maturation, evolving clinical priorities, and new collaborative paradigms that bridge academia and industry. Improved assay sensitivity from innovations in mass spectrometry and next-generation sequencing has reduced the limit of detection for low-abundance analytes, thereby expanding the range of measurable targets and increasing the clinical utility of peripheral and cerebrospinal fluid biomarkers. Simultaneously, immunoassay refinements, including high-affinity reagents and automated platforms, have enhanced reproducibility across clinical laboratories.

Equally important, translational priorities have shifted toward multimodal biomarker strategies that combine genomic, proteomic, and metabolomic data to provide a more holistic view of central nervous system disease biology. This integrative approach supports stratified clinical trial designs and fosters adaptive protocols that can respond to interim biomarker readouts. In addition, the adoption of standardized pre-analytical protocols and reference materials has improved inter-laboratory comparability, enabling multi-site studies to produce analyzable biomarker endpoints with greater confidence.

On the commercialization front, partnerships between diagnostic developers and pharmaceutical sponsors have intensified to co-develop companion diagnostics and surrogate endpoints, thereby shortening the pathway from discovery to clinical adoption. Finally, advances in bioinformatics and machine learning applied to longitudinal biomarker datasets are revealing novel endophenotypes and predictive patterns, which supports more precise patient selection and risk modeling. Taken together, these shifts accelerate translational momentum and reshape investment priorities across R&D and clinical operations.

Comprehensive analysis of how updated United States tariff policies in 2025 have affected reagent supply chains, assay sourcing decisions, and operational resilience in biomarker workflows

Policy and trade instruments implemented in 2025, including revised tariff schedules and customs procedures, have produced cumulative impacts on supply chains, reagent sourcing, and the cost base for central nervous system biomarker development. Import levies and procedural delays have tended to increase lead times for specialized reagents, antibody kits, mass spectrometry consumables, and sequencing reagents that are often sourced globally. As a consequence, procurement teams and laboratory managers have re-evaluated inventory strategies, moved to more diversified supplier portfolios, and accelerated qualification of alternative reagent sources to preserve study timelines.

Beyond supply delays, tariffs have influenced decisions around regional manufacturing and reagent localization. Companies with sufficient scale have explored onshore or nearshore production of critical reagents and assay components to reduce exposure to cross-border duties and customs volatility. At the same time, smaller firms and academic groups have collaborated with contract manufacturing organizations and reagent distributors to access pre-qualified materials without the capital expense of new production facilities.

Regulatory interactions have also been affected because increased unit costs and extended delivery windows can complicate multi-center clinical studies that require synchronized sample collection and assay runs. To manage these risks, sponsors have adopted staggered enrollment windows, centralized testing hubs, and enhanced cold-chain logistics. Moreover, tariffs have prompted greater emphasis on validating assays with multiple reagent sources to avoid single-source dependencies that would be vulnerable to trade disruptions.

Finally, the macroeconomic ripple effects of tariff-related cost pressure have stimulated operational efficiencies, such as higher-throughput platforms, assay miniaturization, and batch consolidation, which help dilute per-assay overhead. While tariffs present near-term logistical and cost management challenges, they have also catalyzed strategic adaptations that reinforce supply resilience and operational agility.

Deep segmentation intelligence synthesizing biomarker types, disease indications, technologies, applications, and end-user roles to inform strategic prioritization and translational planning

Insightful segmentation analysis reveals distinct dynamics across different biomarker types, disease indications, technological modalities, applications, and end-user constituencies, each shaping pathways to clinical impact. Within biomarker type, genomic biomarkers deliver information about inherited and somatic variation that can clarify disease mechanisms and patient stratification, while metabolomic biomarkers offer sensitive readouts of biochemical pathway perturbations; proteomic biomarkers provide direct measures of protein abundance, post-translational modifications, and aggregated species that often correlate closely with neuropathology. These complementary modalities are increasingly used in concert to create multilayered molecular signatures.

Regarding disease indications, neurodegenerative diseases demand biomarkers that can detect early pathology and track progression, enabling intervention well before irreversible neuronal loss. Neurodevelopmental disorders require biomarkers that capture developmental trajectory deviations and support early intervention strategies. Psychotic disorders rely on biomarkers that can delineate heterogeneous clinical syndromes and guide therapeutic matching. Across technological approaches, immunoassay platforms such as ELISA and Western blot provide established, accessible methods for targeted protein detection, while mass spectrometry approaches, including gas chromatography coupled and liquid chromatography coupled workflows, offer high-resolution profiling of small molecules and peptides. Next-generation sequencing methodologies, with both targeted sequencing and whole genome sequencing options, deliver comprehensive genomic landscapes that support variant discovery and molecular classification.

Applications range from diagnosis and therapeutics to drug discovery and development, personalized medicine, prognosis, and research and development. Diagnostic and therapeutic programs benefit when biomarkers demonstrate clinical relevance and analytical rigor, while drug discovery initiatives leverage molecular readouts for target validation and pharmacodynamic assessment. Personalized medicine efforts depend on actionable biomarkers that can guide therapeutic selection, and prognosis-focused research requires markers with reproducible longitudinal performance. Across end users, academic research institutes drive early discovery and assay validation, healthcare providers translate biomarkers into clinical workflows, and pharmaceutical companies integrate biomarkers into clinical development and regulatory interactions. This segmentation framework underscores the need for cross-cutting strategies that align technological selection, intended application, and user capability to maximize translational value.

Regional intelligence revealing how capabilities, regulatory environments, and infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape biomarker adoption and study design

Regional insight highlights divergent capabilities, infrastructure maturity, and regulatory environments that shape how central nervous system biomarkers are discovered, validated, and adopted across geographies. In the Americas, centers of excellence in both academic research and biotech innovation facilitate rapid translation of novel assays into clinical studies, with an established ecosystem of contract research and central laboratory services that supports complex multicenter programs. Meanwhile, reimbursement dynamics and payer engagement play a central role in adoption within clinical practice, prompting early economic evidence generation alongside analytical validation.

In Europe, Middle East & Africa, regulatory harmonization efforts and pan-national collaborative networks support multi-site studies and standardized biomarker protocols, although heterogeneity in healthcare infrastructure across the region affects the pace of clinical implementation. Funding priorities and public-private partnerships frequently drive cross-border consortia that address neurodegenerative disease cohorts and longitudinal registries. The region also benefits from robust analytical capacity in specialized laboratories and a strong tradition of longitudinal epidemiological cohorts that supply valuable biospecimens.

Asia-Pacific presents a contrasting mix of rapid clinical trial expansion, large patient populations, and growing domestic manufacturing capability for reagents and instruments. Investments in high-throughput sequencing and mass spectrometry platforms are increasing, and regulatory authorities are evolving frameworks that accommodate biomarker-based studies. Collectively, these regional dynamics influence sponsor decisions about trial site selection, laboratory partnerships, and localization of manufacturing, with implications for assay standardization, data harmonization, and regulatory dossier preparation across jurisdictions.

Competitive and collaborative dynamics among diagnostic developers and service providers revealing strategies for platform differentiation, partnership formation, and regulatory readiness

Competitive and collaborative behaviors among companies active in central nervous system biomarkers reflect differentiated strategies around platform specialization, partnerships with clinical sites, and value-added services. Some organizations focus on developing deeply validated assay platforms that emphasize analytical performance and regulatory readiness suitable for clinical deployment. These players invest heavily in reagent quality, lot-to-lot consistency, and external validation studies to establish clinical credibility. Conversely, other companies pursue integrated solutions that bundle assay chemistry with data analytics, clinical trial support, and regulatory consulting to lower the barrier for sponsors seeking biomarker-enabled endpoints.

Partnership models have proliferated, encompassing co-development agreements with pharmaceutical sponsors, licensing of proprietary biomarker panels to diagnostic laboratories, and collaborations with academic centers to access longitudinal cohorts. Strategic alliances also extend to contract research organizations and central labs to offer turnkey services that manage sample logistics, assay execution, and data harmonization. In addition, firms differentiate through investments in automated, high-throughput instrumentation and in software that enables standardized analysis pipelines and secure data sharing across study stakeholders.

Mergers and acquisitions continue to be an important avenue for capability acquisition, especially when companies seek to combine assay portfolios with clinical validation expertise or expand geographic reach. Quality management systems and regulatory track records remain critical competitive levers, as does the ability to deliver robust documentation, reference standards, and external proficiency testing. Ultimately, companies that align technological excellence with pragmatic service offerings and regulatory strategy position themselves to capture long-term partnerships with clinical and pharmaceutical customers.

Actionable strategic recommendations for industry leaders to accelerate biomarker validation, fortify supply chains, and align regulatory and commercial pathways for clinical adoption

Leaders in industry and clinical research should act decisively to translate biomarker potential into sustained clinical and commercial value by executing a set of coordinated priorities. First, invest in assay robustness and cross-site standardization early in development to reduce downstream validation friction; this includes developing reference materials, harmonized pre-analytical protocols, and inter-laboratory comparability studies. Second, integrate multimodal biomarker strategies that combine genomic, proteomic, and metabolomic readouts to improve diagnostic precision and trial enrichment, while ensuring that data integration pipelines maintain traceability and interpretability.

Third, strengthen supply chain resilience by qualifying multiple reagent sources, partnering with regional manufacturers when feasible, and adopting inventory strategies that mitigate tariff and customs risks. Fourth, align biomarker deployment with regulatory expectations by engaging early with regulatory bodies, documenting clinical utility, and planning analytical validation that meets clinical-laboratory standards. Fifth, develop commercial pathways that marry clinical evidence with payer engagement, producing health economic analyses that support reimbursement discussions.

Finally, prioritize partnerships that accelerate translational milestones: collaborate with academic centers for longitudinal cohorts, with central laboratories for standardized testing, and with technology firms for data analytics and digital phenotyping. By coordinating these initiatives across R&D, regulatory, and commercial functions, leaders can accelerate the clinical integration of biomarkers while managing operational risk and demonstrating value to clinicians and patients.

Transparent mixed-methods research approach combining expert interviews, technical literature review, and data triangulation to underpin findings and operational recommendations for biomarker development

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure a robust evidence base and triangulated findings across multiple data streams. Primary research included in-depth interviews with key opinion leaders in neurology and psychiatry, assay development scientists, clinical operations leads, and laboratory directors to capture experiential insights on assay performance, operational bottlenecks, and adoption drivers. These conversations informed the interpretation of technical advances and translational barriers.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to contextualize technological progress and regulatory trends. Wherever possible, assay validation literature and analytical performance studies were examined to assess reproducibility and clinical relevance. Data synthesis emphasized cross-validation between primary insights and documented technical performance to minimize bias and enhance credibility.

Analytical rigor was sustained through careful documentation of inclusion criteria for studies and interviews, transparent reporting of methodological limitations, and application of sensitivity checks when interpreting operational and policy impacts. The study explicitly acknowledges constraints related to rapidly evolving technologies and jurisdictional regulatory differences; therefore, conclusions prioritize directional insights and operational implications rather than deterministic predictions. Overall, this mixed-methods approach supports practical, evidence-based recommendations for stakeholders engaged in central nervous system biomarker development and deployment.

Concluding synthesis emphasizing the imperative of robust validation, supply resilience, and cross-sector partnerships to realize the clinical potential of central nervous system biomarkers

In conclusion, central nervous system biomarkers occupy a pivotal role at the intersection of advancing laboratory technologies, clinical need, and translational strategy. The combined strengths of genomic, proteomic, and metabolomic approaches, coupled with improvements in immunoassay, mass spectrometry, and sequencing technologies, have raised the evidentiary bar for clinical utility while creating new opportunities for precision diagnostics and targeted therapeutics. Translational momentum depends on rigorous assay validation, standardized workflows, and strong partnerships that link discovery cohorts with clinical deployment pathways.

Operational challenges such as supply chain disruptions, tariff-driven cost pressures, and heterogeneous regional regulatory frameworks demand proactive mitigation strategies. Companies and research institutions that invest in supply resilience, multi-source validation, and regulatory engagement will be better positioned to navigate these constraints. Moreover, strategic alliances across academia, clinical sites, and industry provide efficient routes to cohort access, centralized testing, and analytic scale.

Ultimately, the future adoption of central nervous system biomarkers will hinge on demonstrable clinical relevance, analytic reproducibility, and clear pathways to reimbursement and clinical integration. Stakeholders who align technological capabilities with pragmatic operational planning and robust evidence generation will advance translational success and create meaningful improvements in patient diagnosis, prognosis, and treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital twin modeling with multi-omics CNS biomarker discovery for personalized therapy selection
  • 5.2. Adoption of blood-brain barrier permeability assays to validate peripheral CNS biomarker candidates in clinical trials
  • 5.3. Use of exosomal microRNA signatures in cerebrospinal fluid as prognostic indicators for early Alzheimer's detection
  • 5.4. Commercial development of PET radioligands targeting synaptic density as quantitative biomarkers in neurodegenerative research
  • 5.5. Implementation of artificial intelligence algorithms to analyze longitudinal biomarker data from CNS disease progression studies
  • 5.6. Collaboration between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics for CNS oncology treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Biomarkers Market, by Type

  • 8.1. Genomic Biomarkers
  • 8.2. Metabolomic Biomarkers
  • 8.3. Proteomic Biomarkers

9. Central Nervous System Biomarkers Market, by Disease Indication

  • 9.1. Neurodegenerative Diseases
  • 9.2. Neurodevelopmental Disorders
  • 9.3. Psychotic Disorders

10. Central Nervous System Biomarkers Market, by Technology

  • 10.1. Immunoassay
    • 10.1.1. ELISA
    • 10.1.2. Western Blot
  • 10.2. Mass Spectrometry
    • 10.2.1. Gas Chromatography Coupled
    • 10.2.2. Liquid Chromatography Coupled
  • 10.3. Next-Generation Sequencing
    • 10.3.1. Targeted Sequencing
    • 10.3.2. Whole Genome Sequencing

11. Central Nervous System Biomarkers Market, by Application

  • 11.1. Diagnosis & Therapeutics
  • 11.2. Drug Discovery & Development
  • 11.3. Personalized Medicine
  • 11.4. Prognosis
  • 11.5. Research & Development

12. Central Nervous System Biomarkers Market, by End-User

  • 12.1. Academic Research Institutes
  • 12.2. Healthcare Providers
  • 12.3. Pharmaceutical Companies

13. Central Nervous System Biomarkers Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Central Nervous System Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Central Nervous System Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Abbvie Inc.
    • 16.3.3. Acumen Pharmaceuticals Inc.
    • 16.3.4. ADx NeuroSciences NV
    • 16.3.5. Agilent Technologies, Inc.
    • 16.3.6. Altoida
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. BioMerieux SA
    • 16.3.10. Bruker Corporation
    • 16.3.11. C2N Diagnostics, LLC
    • 16.3.12. Cerevance, LLC
    • 16.3.13. Charles River Laboratories International, Inc.
    • 16.3.14. Eli Lilly and Co.
    • 16.3.15. F. Hoffmann-La Roche AG
    • 16.3.16. Invicro LLC
    • 16.3.17. Johnson & Johnson Services Inc.
    • 16.3.18. Laboratory Corporation of America Holdings
    • 16.3.19. Mediford Corporation
    • 16.3.20. Merck & Co., Inc.
    • 16.3.21. Myriad Genetics, Inc.
    • 16.3.22. Neurotrack Technologies, Inc.
    • 16.3.23. Novartis AG
    • 16.3.24. Qiagen N.V.
    • 16.3.25. Quanterix Corporation
    • 16.3.26. Sanofi SA
    • 16.3.27. Shimadzu Corporation
    • 16.3.28. Siemens Healthineers
    • 16.3.29. SynapCell
    • 16.3.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 20